News
Public · Published
Moderna's stock jumps after biotech raises sales outlook
Moderna raised its full-year 2026 revenue growth outlook to 15%–25%, up from its previous guidance of 10%. Its revenue rose 29% to $1.3 billion in the third quarter, while its stock surged 10% in premarket trading on Friday.
Published:
Updated:
What happened
Moderna raised its full-year 2026 revenue growth outlook to 15%–25%, up from its previous guidance of 10%. Its revenue rose 29% to $1.3 billion in the third quarter, while its stock surged 10% in premarket trading on Friday.
Confirmed
Global impact / market context
Higher expected revenue can support cash available for research, manufacturing and other company costs, though the article does not say how much growth will come from each product. Because nearly all revenue still comes from Spikevax, sales of the COVID vaccine remain central to whether Moderna meets its outlook.
Analyst inference
The article links Moderna's recent stock gains to expectations for its experimental cancer vaccine, while Friday's premarket jump followed the higher sales outlook. These are distinct drivers: investors are weighing future vaccine prospects alongside near-term revenue, which still relies heavily on Spikevax.
Analyst inference
What to watch
- Check whether Moderna reports revenue growth within its new 15%–25% range for 2026, and whether actual sales support the outlook it announced Friday. Analyst inference
- Watch for separate sales figures for mFlusiva and the RSV vaccine; the article says Moderna did not provide them, limiting visibility into revenue beyond Spikevax. Confirmed
- Follow updates on the experimental cancer vaccine, since the article says expectations for it have helped drive recent stock gains, but gives no trial or launch details. Analyst inference
Evidence
- Original source link unavailable